Comparable stake leader
Deep Track Capital, LP
SEC ownership of CorMedix Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001410098.
Disclosed value leader
Deep Track Capital, LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- CRMD on Nasdaq
- Parsed ownership sources
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- Deep Track Capital, LP
- Latest 13D/G holder
- Deep Track Capital, LP
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001410098
- Issuer location
- Parsippany, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CorMedix Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Deep Track Capital, LP
Disclosed value leader
Deep Track Capital, LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.9%
13D/G row: Deep Track Capital, LP
Showing 1-8 of 50 holder rows.
Quick read
Deep Track Capital, LP leads the comparable SEC ownership view at 7.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Deep Track Capital, LP's linked filing trail.
Comparable ownership
Top 5
Deep Track Capital, LP
7.9%
BlackRock, Inc.
7.5%
Aymen Abdalkader Shaibatalhamd
5.8%
Elizabeth Hurlburt
0.35%
Myron Kaplan
0.33%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Deep Track Capital, LP |
13D/G
13F
Company
|
7.9%
|
$44,985,125
6,274,076 shares
|
+$9,454,283 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
7.5%
|
$41,659,221
4,567,897 shares
|
$0 | 31 Dec 2024 |
| Aymen Abdalkader Shaibatalhamd |
13D/G
SHAIBATALHAMD AYMEN ABDALKADER
|
5.8%
|
$44,390,000
4,600,000 shares
|
-$440,330 | 01 Jan 2026 |
| Elizabeth Hurlburt |
3/4/5
Chief Operating Officer
|
0.35%
|
$1,966,485
278,539 shares
|
-$711,817 | 04 Feb 2026 |
| Myron Kaplan |
3/4/5
Director
|
0.33%
|
$3,041,093
261,487 shares
|
+$275,500 | 26 Jan 2026 |
| Steven W. Lefkowitz |
3/4/5
Director
|
0.2%
|
$1,838,737
158,103 shares
|
-$475,200 | 26 Jan 2026 |
| Michael David Seckler |
3/4/5
Chief Commercial Officer
|
0.17%
|
$1,548,604
133,156 shares
|
— | 08 Jan 2026 |
| Susan Blum |
3/4/5
Chief Financial Officer
|
0.17%
|
$965,012
132,739 shares
|
— | 23 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,530,637.
Buys
$275,500
Insiders: 1
Sells
$4,806,137
Insiders: 6
Net
-$4,530,637
Shares: -375,997
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 25,000
Shares: 400,997
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 134,000 | $0 | $1,572,000 | -$1,572,000 |
| 6-9 | 25,000 | 266,997 | $275,500 | $3,234,137 | -$2,958,637 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to CorMedix Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Joseph Todisco
Net 12M change
-$4,530,637
Latest report
04 Feb 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joseph Todisco | Chief Executive Officer, Director | $5,469,727 | -$1,010,000 | -16% | Mixed | 04 Feb 2026 |
| Myron Kaplan | Director | $3,041,093 | +$275,500 | +10% | Mixed | 26 Jan 2026 |
| Elizabeth Hurlburt | Chief Operating Officer | $1,966,485 | -$711,817 | -27% | Mixed | 04 Feb 2026 |
| Beth Zelnick Kaufman | Chief Legal Officer | $1,899,902 | -$670,264 | -26% | Mixed | 04 Feb 2026 |
| Steven W. Lefkowitz | Director | $1,838,737 | -$475,200 | -21% | Mixed | 26 Jan 2026 |
| Michael David Seckler | Chief Commercial Officer | $1,548,604 | Mixed | 08 Jan 2026 | ||
| Erin Mistry | EVP, Chief Commercial Officer | $1,130,100 | Mixed | 10 Jan 2025 | ||
| David Matthew T. | Chief Financial Officer | $1,066,071 | Mixed | 10 Jan 2025 | ||
| Susan Blum | Chief Financial Officer | $965,012 | Mixed | 23 Jan 2026 | ||
| Alan W. Dunton | Director | $822,275 | -$391,300 | -32% | Mixed | 26 Jan 2026 |
| Janet Dillione | Director | $801,609 | -$1,547,556 | -66% | Mixed | 26 Jan 2026 |
| Gregory Scott Duncan | Director | $799,981 | Mixed | 26 Jan 2026 | ||
| Robert A. Stewart | Director | $772,848 | Mixed | 26 Jan 2026 | ||
| Paulo F. Costa | Director | $34,700 | Mixed | 17 May 2023 | ||
| Phoebe Mounts | General Counsel | $24,984 | Mixed | 14 Jan 2023 | ||
| Thomas Nusbickel | EVP, Chief Commercial Officer | Mixed | 18 Feb 2022 |
Recent insider transactions for CorMedix Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Beth Zelnick Kaufman | CRMD | Common Stock | Award | 15.4% | 36,006 | 269,108 | 04 Feb 2026 | Direct | ||
| Elizabeth Hurlburt | CRMD | Common Stock | Award | 14.8% | 36,006 | 278,539 | 04 Feb 2026 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Award | 11.1% | 77,156 | 774,749 | 04 Feb 2026 | Direct | ||
| Robert A. Stewart | CRMD | Common Stock | Award | 84.6% | 30,453 | 66,453 | 26 Jan 2026 | Direct | ||
| Janet Dillione | CRMD | Common Stock | Award | 79.2% | 30,453 | 68,926 | 26 Jan 2026 | Direct | ||
| Myron Kaplan | CRMD | Common Stock | Award | 15.2% | 30,453 | 231,487 | 26 Jan 2026 | Direct | ||
| Gregory Scott Duncan | CRMD | Common Stock | Award | 79.4% | 30,453 | 68,786 | 26 Jan 2026 | Direct | ||
| Steven W. Lefkowitz | CRMD | Common Stock | Award | 31.9% | 30,453 | 125,951 | 26 Jan 2026 | Direct | ||
| Alan W. Dunton | CRMD | Common Stock | Award | 75.7% | 30,453 | 70,703 | 26 Jan 2026 | Direct | ||
| Susan Blum | CRMD | Common Stock | Tax liability | -6.85% | -9,767 | 132,739 | 23 Jan 2026 | Direct | ||
| Susan Blum | CRMD | Common Stock | Award | 104.5% | 72,820 | 142,506 | 23 Jan 2026 | Direct | ||
| Beth Zelnick Kaufman | CRMD | Common Stock | Tax liability | -3.64% | -8,803 | 233,102 | 23 Jan 2026 | Direct | ||
| Beth Zelnick Kaufman | CRMD | Common Stock | Award | 43.1% | 72,820 | 241,905 | 23 Jan 2026 | Direct | ||
| Elizabeth Hurlburt | CRMD | Common Stock | Tax liability | -4.25% | -10,778 | 242,533 | 23 Jan 2026 | Direct | ||
| Elizabeth Hurlburt | CRMD | Common Stock | Award | 58% | 93,010 | 253,311 | 23 Jan 2026 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Tax liability | -3.77% | -27,306 | 697,593 | 23 Jan 2026 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Award | 45.3% | 225,900 | 724,899 | 23 Jan 2026 | Direct | ||
| Janet Dillione | CRMD | Common Stock | Sale | -20.6% | $68,800 | $6.88 | -10,000 | 38,473 | 21 Jan 2026 | Direct |
| Joseph Todisco | CRMD | Common Stock | Tax liability | -4.34% | -22,665 | 498,999 | 17 Jan 2026 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Options Exercise | 6.01% | 29,585 | 521,664 | 16 Jan 2026 | Direct | ||
| Joseph Todisco | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -6.71% | -29,585 | 411,245 | 16 Jan 2026 | Direct | ||
| Elizabeth Hurlburt | CRMD | Common Stock | Tax liability | -3.49% | -5,794 | 160,301 | 12 Jan 2026 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Tax liability | -3.42% | -17,417 | 492,079 | 12 Jan 2026 | Direct | ||
| Steven W. Lefkowitz | CRMD | Common Stock | Options Exercise | 18.6% | 15,000 | 95,498 | 12 Jan 2026 | Direct | ||
| Steven W. Lefkowitz | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -100% | -15,000 | 0 | 12 Jan 2026 | Direct | ||
| Michael David Seckler | CRMD | Common Stock | Award | 133,156 | 133,156 | 08 Jan 2026 | Direct | |||
| Elizabeth Hurlburt | CRMD | Common Stock | Tax liability | -6.16% | -10,895 | 166,095 | 02 Jan 2026 | Direct | ||
| Beth Zelnick Kaufman | CRMD | Common Stock | Tax liability | -6.28% | -11,333 | 169,085 | 02 Jan 2026 | Direct | ||
| Alan W. Dunton | CRMD | Common Stock | Sale | -33.2% | $260,000 | $13.00 | -20,000 | 40,250 | 30 Dec 2025 | Direct |
| Alan W. Dunton | CRMD | Common Stock | Options Exercise | 49.7% | 20,000 | 60,250 | 30 Dec 2025 | Direct | ||
| Alan W. Dunton | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -100% | -20,000 | 0 | 30 Dec 2025 | Direct | ||
| Joseph Todisco | CRMD | Common Stock | Sale | -5.56% | $360,000 | $12.00 | -30,000 | 509,496 | 18 Dec 2025 | Direct |
| Joseph Todisco | CRMD | Common Stock | Options Exercise | 5.89% | 30,000 | 539,496 | 18 Dec 2025 | Direct | ||
| Joseph Todisco | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -7.5% | -30,000 | 370,000 | 18 Dec 2025 | Direct | ||
| Janet Dillione | CRMD | Common Stock | Sale | -41.2% | $408,000 | $12.00 | -34,000 | 48,473 | 09 Dec 2025 | Direct |
| Janet Dillione | CRMD | Common Stock | Options Exercise | 70.1% | 34,000 | 82,473 | 09 Dec 2025 | Direct | ||
| Janet Dillione | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -100% | -34,000 | 0 | 09 Dec 2025 | Direct | ||
| Steven W. Lefkowitz | CRMD | Common Stock | Sale | -33.2% | $475,200 | $11.88 | -40,000 | 80,498 | 09 Dec 2025 | Direct |
| Janet Dillione | CRMD | Common Stock | Sale | -49% | $466,570 | $10.00 | -46,657 | 48,473 | 02 Dec 2025 | Direct |
| Janet Dillione | CRMD | Common Stock | Options Exercise | 96.2% | 46,657 | 95,130 | 02 Dec 2025 | Direct | ||
| Janet Dillione | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -100% | -46,657 | 0 | 02 Dec 2025 | Direct | ||
| Janet Dillione | CRMD | Common Stock | Sale | -35.2% | $261,586 | $9.93 | -26,343 | 48,473 | 24 Nov 2025 | Direct |
| Janet Dillione | CRMD | Common Stock | Options Exercise | 54.4% | 26,343 | 74,816 | 24 Nov 2025 | Direct | ||
| Janet Dillione | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -100% | -26,343 | 0 | 24 Nov 2025 | Direct | ||
| Janet Dillione | CRMD | Common Stock | Sale | -38.2% | $342,600 | $11.42 | -30,000 | 48,473 | 14 Nov 2025 | Direct |
| Myron Kaplan | CRMD | Common Stock | Purchase | 14.2% | $275,500 | $11.02 | 25,000 | 201,034 | 23 Oct 2025 | Direct |
| Gregory Scott Duncan | CRMD | Common Stock | Options Exercise | 53.3% | 13,333 | 38,333 | 16 Sep 2025 | Direct | ||
| Gregory Scott Duncan | CRMD | Stock Option (Right to Buy Common Stock) | Options Exercise | -66.7% | -13,333 | 6,667 | 16 Sep 2025 | Direct | ||
| Alan W. Dunton | CRMD | Common Stock | Sale | -19.9% | $131,300 | $13.13 | -10,000 | 40,250 | 12 Sep 2025 | Direct |
| Alan W. Dunton | CRMD | Common Stock | Options Exercise | 24.8% | 10,000 | 50,250 | 12 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.